肥胖症治療市場規模、佔有率及成長分析（按手術類型、藥物類型、最終用戶和地區分類）－2026-2033年產業預測

全球肥胖治療市場規模預計在 2024 年達到 97 億美元，從 2025 年的 100.2 億美元成長到 2033 年的 129.9 億美元，在預測期（2026-2033 年）內複合年成長率為 3.3%。

隨著醫療保健機構積極應對肥胖症盛行率及其相關健康風險的急劇上升，全球肥胖症治療市場正在迅速擴張。肥胖與糖尿病、心血管疾病和多種癌症等嚴重密切相關，因此迫切需要創新的治療方案。導致肥胖症流行的因素包括久坐不動的生活方式、不良的飲食習慣和遺傳傾向。藥物療法，例如食慾抑制劑和促進能量消耗的藥物，與減肥手術等醫療設備手術方案一起發揮重要作用。此外，旨在控制食量和以營養與運動為中心的身臨其境型生活方式介入計畫對於長期療效也至關重要。在人們對肥胖症健康影響的認知不斷提高的推動下，該市場為相關人員之間的技術進步、投資和合作提供了豐富的機會。

全球肥胖症治療市場促進因素

全球肥胖症發生率的不斷上升是推動肥胖症治療市場發展的主要因素。久坐不動的生活方式、不良的飲食習慣以及遺傳傾向等因素進一步加劇了這一日益嚴重的健康危機。隨著肥胖症相關健康風險的日益凸顯，對有效治療方案的需求也持續飆升。人們對肥胖症健康影響的認知不斷提高，促使個人和醫療系統尋求可靠且創新的治療方法，這進一步推動了肥胖症治療產業的成長。因此，市面上有效治療方案的研發和普及程度顯著提高。

限制全球肥胖治療市場的因素

全球肥胖治療市場面臨的主要障礙之一是肥胖相關治療的保險覆蓋範圍有限或缺乏。保險公司通常會設定嚴格的條件，要求患者達到特定的BMI值或提供先前減重失敗的證明，才能獲得治療核准。這種保險覆蓋範圍的不足限制了患者獲得必要治療的機會，最終削弱了肥胖管理工作的有效性。保險覆蓋不足帶來的挑戰可能導致許多人無法獲得必要的干涉措施，從而加劇肥胖流行，並阻礙人群健康狀況的改善。

全球肥胖症治療市場趨勢

全球肥胖治療市場正經歷著向個人化醫療的顯著轉變，這種轉變將肥胖視為一種受遺傳、代謝和生活方式因素影響的多面向疾病。基因組研究和生物標記識別的重大進展推動了這一轉變，為個人化治療策略鋪平了道路。專業人士越來越關注精準醫療和標靶治療，以應對每個人的獨特特徵，從而提高治療效果和依從性。隨著醫療服務提供者致力於最佳化治療結果，個人化肥胖管理方法的整合有望推動市場創新和成長，為患者提供更有效的解決方案。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術進步

全球肥胖症治療市場規模（按手術類型和複合年成長率分類）（2026-2033 年）

• 膽胰分流術伴隨十二指腸轉位術（BPD/DS）
• 胃束帶調整
• Roux-en-Y胃繞道手術
• 袖狀切除術
• 內視鏡手術

全球肥胖症治療市場規模（按藥物類型和複合年成長率分類）（2026-2033 年）

• 食慾抑制劑
• 複方藥物
• 吸收不良
• 飽腹藥物

全球肥胖症治療市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 美容設施
• 其他

全球肥胖症治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Roche（Switzerland）
• GlaxoSmithKline（GSK）（United Kingdom）
• AstraZeneca（United Kingdom）
• Johnson & Johnson（United States）
• Sanofi（France）
• Pfizer（United States）
• Amgen（United States）
• Boehringer Ingelheim（Germany）
• Medtronic（Ireland）
• Altimmune（United States）
• Viking Therapeutics（United States）
• Structure Therapeutics（United States）
• NovoCure（United States）
• Arena Pharmaceuticals（United States）
• Rhythm Pharmaceuticals（United States）
• Zafgen（United States）
• Vivus（United States）

結論與建議

Global Obesity Treatment Market size was valued at USD 9.7 Billion in 2024 and is poised to grow from USD 10.02 Billion in 2025 to USD 12.99 Billion by 2033, growing at a CAGR of 3.3% during the forecast period (2026-2033).

The global obesity treatment market is expanding rapidly as healthcare providers respond to the alarming rise in obesity prevalence and its related health risks. As obesity is linked to serious conditions like diabetes, cardiovascular diseases, and various cancers, there is an urgent demand for innovative treatment solutions. Factors contributing to this epidemic include sedentary lifestyles, poor dietary choices, and genetic predispositions. Pharmaceutical interventions, including appetite suppressants and medications that enhance energy expenditure, play a vital role, alongside surgical options such as bariatric procedures. Moreover, medical devices designed for portion control and immersive lifestyle programs centered on nutrition and exercise are essential for long-term success. Driven by heightened awareness of obesity's health impacts, this market presents ample opportunities for advancement, investment, and collaboration among stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Obesity Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Obesity Treatment Market Segments Analysis

Global Obesity Treatment Market is segmented by Surgery Type, Drug Type, End User and region. Based on Surgery Type, the market is segmented into Biliopancreatic diversion with Duodenal Switch (BPD/DS), Adjusting Gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy and Endoscopic Procedures. Based on Drug Type, the market is segmented into Appetite suppressants, Combination drugs, Malabsorption and Satiety drugs. Based on End User, the market is segmented into Hospital, Clinics, Beauty institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Obesity Treatment Market

The increasing worldwide incidence of obesity stands as a major catalyst for the obesity treatment market. Contributing factors like sedentary lifestyles, poor dietary choices, and genetic tendencies have exacerbated this escalating health crisis. As the associated health risks linked to obesity become more apparent, the demand for effective treatment solutions continues to surge. This heightened awareness of the medical implications of obesity propels both individuals and healthcare systems to seek reliable and innovative therapies, further stimulating growth within the obesity treatment sector. As a result, the market is witnessing a significant enhancement in the development and availability of effective treatment options.

Restraints in the Global Obesity Treatment Market

A significant barrier in the Global Obesity Treatment market is the limited or absent insurance coverage for obesity-related therapies. Insurance companies often impose stringent criteria, necessitating that patients achieve certain BMI levels or show evidence of unsuccessful prior weight loss methods before approval for treatment. This lack of extensive insurance support restricts access to essential therapies, ultimately undermining the effectiveness of obesity management efforts. The challenges posed by inadequate coverage can prevent many individuals from receiving the necessary interventions, thereby exacerbating the prevalence of obesity and hindering overall health improvements within the population.

Market Trends of the Global Obesity Treatment Market

The Global Obesity Treatment market is witnessing a notable trend towards personalized medicine, recognizing obesity as a multifaceted condition shaped by genetic, metabolic, and lifestyle factors. This shift is fueled by significant advancements in genomic research and biomarker identification, paving the way for customized treatment strategies. Professionals are increasingly focusing on precision medications and targeted therapies that address the unique characteristics of each individual, enhancing treatment efficacy and adherence. As healthcare providers look to optimize outcomes, the integration of tailored approaches into obesity management is expected to drive innovation and growth within the market, offering patients more effective solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Obesity Treatment Market Size by Surgery Type & CAGR (2026-2033)

• Market Overview
• Biliopancreatic diversion with Duodenal Switch (BPD/DS)
• Adjusting Gastric Banding
• Roux-en-Y Gastric Bypass
• Sleeve gastrectomy
• Endoscopic Procedures

Global Obesity Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Appetite suppressants
• Combination drugs
• Malabsorption
• Satiety drugs

Global Obesity Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital
• Clinics
• Beauty institutions
• Others

Global Obesity Treatment Market Size & CAGR (2026-2033)

• North America (Surgery Type, Drug Type, End User)
  • US
  • Canada
• Europe (Surgery Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Surgery Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Surgery Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Surgery Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altimmune (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Structure Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NovoCure (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arena Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zafgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivus (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations